They are included for research and educational reference only
In placebo-controlled trials of semaglutide injection for type 2 diabetes mellitus, fatigue, dysgeusia, and dizziness were reported in greater than 0.4% of semaglutide-treated patients
PMID: 38024099
While the presence of aggregated biological macromolecules can occur in vivo , this work focuses on the detection of in vitro peptide aggregation
its up to the FDA, and right now, these specific peptides sit outside it. The biggest risk to this potential pathway, Robinson explains, is reporting of adverse events, which the FDA describes as any undesirable experience associated with the use of a medical product in a patient. Should an adverse event happen, Robinson says it could negatively impact or delay the rulemaking process. As the FDA pointed out in their official meeting recommendation to keep the peptides under their current restrictions, these peptides simply dont have adequate clinical data behind them
Tay LX, Ong SC, Tay LJ et al (2024) Economic burden of Alzheimers disease: a systematic review